Project Grant R01CA299955
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$627K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis.
The first approach involves enzymatic inactivation of colibactin through...
This $581,087 federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research at the University of Chicago to investigate the use of genetically-engineered Bifidobacterium bacteria for enhancing cancer immunotherapy and radiotherapy. The project aims to develop a novel approach where systemically administered Bifidobacterium can selectively colonize tumors and secrete human IL-2 to stimulate anti-tumor...
This $400,890 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to profile patient-specific tumor-microbiome interactions and quantitatively analyze the impact on immune checkpoint molecules in colorectal tumors that are unresponsive to immune checkpoint inhibitor immunotherapy. The project will utilize a pathomimetic colorectal cancer organ-on-a-chip model with patient-derived tumor or normal organoids to elucidate the...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is providing $697,763 to The University of Texas MD Anderson Cancer Center to support research aimed at deciphering the critical determinants of how the bacteria Fusobacterium nucleatum (F. nucleatum) colonizes the colorectal cancer (CRC) tumor microenvironment. The research team will investigate specific genetic factors in a CRC-associated clade of F. nucleatum that appear to enable...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $253,405 to The Trustees of Columbia University in the City of New York to conduct research aimed at improving bacterial cancer therapeutics. The project seeks to identify pathways enabling bacteria like E. coli to specifically migrate to and grow within tumors, with the goal of increasing the tumor specificity and colonization efficiency of bacterial cancer therapies. Through...
This $235,620 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research focused on the development and testing of MTDIA, a novel transition state inhibitor of MTAP, for the prevention and treatment of inflammation-associated colorectal cancer.
The grant funds preclinical studies in two unique mouse models of sporadic colon tumors and rectal tumors driven by inflammation. The research aims to evaluate the efficacy of MTDIA and improved...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University (Stanford University) in the amount of $179,988 will support research to identify bacterial functions that enhance the effectiveness of cancer immunotherapy. The overarching goal is to understand how the gut microbiome can impact cancer patients' responses to immune checkpoint blockade therapies.
The key activities under this award include...
The National Cancer Institute (NCI) awarded a $678,399 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The study aims to evaluate the effects of a prebiotic food-enriched diet on the gut microbiome, immune response, and treatment outcomes for metastatic melanoma patients receiving immune checkpoint inhibitor (ICI) therapy. The research will investigate whether manipulating...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the role of the gut-breast axis and gut microbiome in breast cancer pathophysiology. Specifically, the $620,959 award, effective from April 5, 2024 through March 31, 2026, aims to investigate whether the gut microbiomes of mice susceptible or resistant to HER2-positive mammary tumors exert pro-tumor or anti-tumor effects, and...
This $1,384,482 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to determine if DNA methyltransferases from members of the microbiota, specifically Fusobacterium nucleatum (Fn), contribute to bacterial pathoadaptation in the tumor niche and can interfere with the human host epigenome in cancer.
The primary awardee, The University of Texas MD Anderson Cancer Center, will conduct experiments to evaluate how the Fn...